Heparin
- Generic Name
- Heparin
- Brand Names
- Heparin Leo
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- T2410KM04A
- Background
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...
- Indication
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...
- Associated Conditions
- Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein
- Associated Therapies
- Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
- Conditions
- Interventions
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2019-10-15
- Lead Sponsor
- Momenta Pharmaceuticals, Inc.
- Target Recruit Count
- 503
- Registration Number
- NCT00543400
- Locations
- 🇺🇸
The Methodist Hospital, Houston, Texas, United States
🇺🇸University of Michigan Health System, Ann Arbor, Michigan, United States
🇨🇦University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
- Conditions
- Interventions
- First Posted Date
- 2007-07-30
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 140
- Registration Number
- NCT00508924
Anticoagulation in Blunt Cerebrovascular Injuries
- Conditions
- First Posted Date
- 2007-06-29
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- C. Clay Cothren, MD
- Registration Number
- NCT00494156
- Locations
- 🇺🇸
Denver Health Medical Center, Denver, Colorado, United States
A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2012-07-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 3254
- Registration Number
- NCT00451412
- Locations
- 🇩🇪
Novartis investigative sites, Nürnberg, Germany
Antithrombotic Regimens and Outcome
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2009-02-10
- Lead Sponsor
- Careggi Hospital
- Target Recruit Count
- 850
- Registration Number
- NCT00448461
- Locations
- 🇮🇹
Division of Cardiology, Careggi Hospital, Florence, Italy
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
- Conditions
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00445328
- Locations
- 🇮🇳
Pfizer Investigational Site, Kolkata, West Bengal, India
HEROIC (Heparin Requirement in Counterpulsation)
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 46
- Registration Number
- NCT00445211
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
Enoxaparin Versus Unfractionated Heparin in PCI
- Conditions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2007-02-26
- Lead Sponsor
- Triemli Hospital
- Target Recruit Count
- 2100
- Registration Number
- NCT00439855
- Locations
- 🇨🇭
Division of Cardiology Triemli Hospital Zurich, Zurich, Switzerland
Dalteparin Versus Unfractionated Heparin In Patients With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 173
- Registration Number
- NCT00435487
- Locations
- 🇮🇳
Pfizer Investigational Site, Karnataka, India
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2007-02-12
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- Cardiovascular Research Foundation, New York
- Target Recruit Count
- 3602
- Registration Number
- NCT00433966
- Locations
- 🇺🇸
LeBauer CV Research Foundation, Greensboro, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.